Bottom line
IBB vs BIB: the short answer
IBB (iShares Biotechnology ETF) and BIB (ProShares Ultra Nasdaq Biotechnology) share a meaningful slice of their top holdings — about 44% by weight.
IBB is cheaper at 0.44% vs 0.95% — a difference of $51 a year per $10,000 invested.
Over five years, IBB returned +2.5% a year vs −1.0% for BIB.
Updated Nov 19, 2026
IBB vs BIB side by side
| IBB | BIB | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | iShares | ProShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.44% | 0.95% |
| Annual cost per $10k | $44 | $95 |
| 10-yr cost on $10k (prospectus) | $555 | $1,401 |
| Max front load | None | None |
| 12b-1 fee | 0% | — |
| 1-yr return | +28.0% | +59.3% |
| 5-yr return (annualized) | +2.5% | −1.0% |
| 10-yr return (annualized) | +4.4% | +1.4% |
| Best quarter | +26.8% | +56.2% |
| Worst quarter | −22.9% | −42.7% |
| Net assets (fund) | $5.9B | $73.7M |
| Number of holdings | 254 | 267 |
| Portfolio turnover | 27% | 29% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IBB | BIB | Difference |
|---|---|---|---|
| 2025 | +28.0% | +59.3% | −31.3% |
| 2024 | −2.4% | −10.0% | +7.6% |
| 2023 | +3.6% | −1.3% | +4.9% |
| 2022 | −13.6% | −28.6% | +15.0% |
| 2021 | +1.0% | −5.9% | +6.9% |
| 2020 | +25.9% | +39.7% | −13.8% |
| 2019 | +24.8% | +45.5% | −20.8% |
| 2018 | −9.1% | −24.4% | +15.2% |
| 2017 | +21.2% | +40.8% | −19.6% |
| 2016 | −21.5% | −44.2% | +22.7% |
Source: Fund prospectus bar charts
Holdings overlap
12 of IBB's top 25 holdings also appear in BIB's top 25.
| Holding | IBB | BIB |
|---|---|---|
| Vertex Pharmaceuticals, Inc. | 7.66% | 4.65% |
| Gilead Sciences, Inc. | 7.52% | 4.66% |
| Amgen, Inc. | 7.50% | 4.48% |
| Regeneron Pharmaceuticals, Inc. | 5.70% | 3.21% |
| Alnylam Pharmaceuticals, Inc. | 5.68% | 2.01% |
| Argenx SE | 3.15% | 1.19% |
| Insmed, Inc. | 2.95% | 1.16% |
| Biogen, Inc. | 2.03% | 1.44% |
| United Therapeutics Corp. | 1.82% | 1.22% |
| Incyte Corp. | 1.62% | 0.97% |
| Illumina, Inc. | 1.41% | 1.25% |
| Moderna, Inc. | 0.88% | 0.94% |
Source: SEC Form N-PORT
IBB top 10
- BlackRock Funds III — 13.18%
- Vertex Pharmaceuticals, Inc. — 7.66%
- Gilead Sciences, Inc. — 7.52%
- Amgen, Inc. — 7.50%
- Regeneron Pharmaceuticals, Inc. — 5.70%
- Alnylam Pharmaceuticals, Inc. — 5.68%
- IQVIA Holdings, Inc. — 3.18%
- Argenx SE — 3.15%
- Insmed, Inc. — 2.95%
- Mettler-Toledo International, Inc. — 2.49%
BIB top 10
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- Gilead Sciences, Inc. — 4.66%
- Vertex Pharmaceuticals, Inc. — 4.65%
- Amgen, Inc. — 4.48%
- N/a — 3.94%
- N/a — 3.26%
- Regeneron Pharmaceuticals, Inc. — 3.21%
- N/a — 2.62%
- Alnylam Pharmaceuticals, Inc. — 2.01%
FAQ
What is the difference between IBB and BIB?
Which is cheaper, IBB or BIB?
Should I own both IBB and BIB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.